News

Video

Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study

Author(s):

Ibiayi Dagogo-Jack, MD

CROWN (NCT03052608) is a phase 3 clinical trial evaluating progression free survival with the use of loratinib in patients with advanced ALK+ NSCLC.

Related Videos
Phase 3 AMPLIFY Trial
Hidehito Horinouchi, MD, PhD
RLY-2608
Ewa Kalinka, MD, PhD
BOVen
RMC-6236
Related Content
Alexander Watson, MD, DPhil, FRCPC
January 29th 2025

Tissue-Based NGS May Help Determine Relevant Gene Copy Number Gain Cutpoint for HER2/KRAS/MET in NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Alexander Watson, MD, DPhil, FRCPC
January 23rd 2025

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

TKIs in Second-Line HER2-Mutant NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 21st 2025

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12